Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip
Public ClinicalTrials.gov record NCT03949673. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Study to Evaluate Arthroplasty Specimens in the Phase 3 Fasinumab Program for Osteoarthritis of the Knee and Hip
Study identification
- NCT ID
- NCT03949673
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Enrollment
- 23 participants
Conditions and interventions
Conditions
Interventions
- Fasinumab Drug
- Naproxen Drug
- Diclofenac Drug
- Celecoxib Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 7, 2019
- Primary completion
- Aug 24, 2020
- Completion
- Aug 24, 2020
- Last update posted
- Oct 16, 2023
2019 – 2020
United States locations
- U.S. sites
- 6
- U.S. states
- 5
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Regeneron Research Site | Phoenix | Arizona | 85020 | — |
| Regeneron Research Site | Littleton | Colorado | 80127 | — |
| Regeneron Research Site | Jacksonville | Florida | 32256 | — |
| Regeneron Research Site | Chicago | Illinois | 60611 | — |
| Regeneron Research Site | Brooklyn | New York | 11230 | — |
| Regeneron Research Site | New York | New York | 10036 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03949673, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 16, 2023 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03949673 live on ClinicalTrials.gov.